Ascendis Pharma’s $600 Million ADSs Public Offering


Latham & Watkins LLP represented Ascendis Pharma A/S in the transaction.

Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, announced the pricing of its underwritten public offering of 4,225,352 American Depositary Shares (“ADSs”), which will raise gross proceeds of approximately $600M.

Latham & Watkins LLP represented Ascendis Pharma A/S in the transaction with a corporate team led by Silicon Valley partner Mark Roeder (Picture) with associates John Williams, Traci Biedermann, Tess Bloom, and Christopher Lim. Advice was also provided on compensation and benefits matters by Los Angeles partner Sam Weiner with associate Janet Hsu; on tax matters by Silicon Valley partner Jay Metz with associate Lilly Fang; on intellectual property matters by Silicon Valley partner Judith Hasko with associate Gavin Liu; on FDA regulatory matters by Washington DC partner Ben Haas and Brussels partner Hector Armengod with San Francisco counsel Betty Pang and associates Chad Jennings and Lacey Henry.

Involved fees earner: Héctor Armengod – Latham & Watkins; Lilly Fang – Latham & Watkins; Ben Haas – Latham & Watkins; Judith Hasko – Latham & Watkins; Lacey Henry – Latham & Watkins; Janet Hsu – Latham & Watkins; Chad Jennings – Latham & Watkins; Gavin Liu – Latham & Watkins; James Metz – Latham & Watkins; Betty Pang – Latham & Watkins; Mark Roeder – Latham & Watkins; Samuel Weiner – Latham & Watkins; John Williams – Latham & Watkins;

Law Firms: Latham & Watkins;

Clients: Ascendis Pharma A/S;

Author: Ambrogio Visconti